Incyte Corp logo

Incyte Corp INCY

Market Closed
21 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
63. 22
+0.86
+1.38%
After Hours
$
62. 50
-0.72 -1.14%
13.6B Market Cap
33.14 P/E Ratio
0% Div Yield
9,700,700 Volume
3.57 Eps
$ 62.36
Previous Close
Day Range
62.46 63.81
Year Range
50.27 67.36

INCY Chart

Incyte Corp Profile

Biotechnology Industry
Healthcare Sector
Mr. Herve Hoppenot CEO
NASDAQ (NGS) Exchange
US45337C1027 ISIN
United States Country
2,524 Employees
- Last Dividend
1 Sep 2000 Last Split
4 Nov 1993 IPO Date

Overview

Incyte Corporation is a prominent biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics. With a broad interest in hematology/oncology and inflammation and autoimmunity sectors, Incyte operates both within the United States and on an international scale. Originally founded in 1991 and known as Incyte Genomics Inc., the company underwent a name change to Incyte Corporation in March 2003. It has established a formidable presence in the pharmaceutical industry, not only through the inception of proprietary drugs but also via strategic collaborations and in-license agreements with other leading biotech entities such as Novartis, Lilly, Agenus, Merus, MacroGenics, Syndax, and China Medical System Holdings Limited. Headquartered in Wilmington, Delaware, Incyte holds a pivotal role in pushing forward the boundaries of medical research and patient care in critical disease areas.

Products and Services

  • JAKAFI (ruxolitinib)

    A cornerstone in Incyte's portfolio, JAKAFI is approved for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. Its mechanism targets aberrant signaling pathways to curb disease progression.

  • MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab)

    Designed for patients with relapsed or refractory diffuse large B-cell lymphoma; a testament to Incyte's commitment to addressing unmet needs in oncology.

  • PEMAZYRE (pemigatinib)

    Acts as a fibroblast growth factor receptor kinase inhibitor, targeting oncogenic drivers in various liquid and solid tumor types, showcasing Incyte's innovative approach in targeted cancer therapy.

  • ICLUSIG (ponatinib)

    Approved for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia, providing a targeted therapeutic option for these hematologic cancers.

  • ZYNYZ (retifanlimab-dlwr)

    This drug is deployed in the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma, underscoring the company's dedication to rare oncology indications.

  • OPZELURA cream

    Marketed for the treatment of atopic dermatitis, this offering diversifies Incyte's portfolio into the dermatological field, addressing a common yet challenging chronic skin condition.

In addition to these marketed products, Incyte's clinical stage pipeline showcases a robust commitment to innovation through a variety of compounds under development, including retifanlimab for additional cancers, axatilimab for chronic GVHD, and a range of molecules designed to tackle solid tumors. The depth and breadth of Incyte's clinical research reflect its continuous pursuit of therapeutic advances to improve patient outcomes in areas of significant unmet medical need.

Contact Information

Address: 1801 Augustine Cut-Off
Phone: 302 498 6700